Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era

Table 1 Current stents categorised by stent material, polymer, eluted drug, and shortened dual antiplatelet therapy duration validated for followed by aspirin or P2Y12 inhibitor monotherapy

Stent	Metallic platform	Polymer	Anti-proliferative agent	DAPT duration validated for	Ref.
Onyx Resolute	Cobalt-chromium (has a platinum iridium core)	Permanent	Zotarolimus	1 mo	[5,6]
BioFreedom	Stainless steel	Polymer-free	Biolimus	1 mo1	[7,8]
Biomatrix; Biomatrix Flex	Cobalt-chromium	Bioresorbable	Biolimus	Standard/no short DAPT	[9,10]
Nobori	Cobalt-chromium	Bioresorbable	Biolimus	6 mo	[11]
Xience	Cobalt-chromium	Permanent	Everolimus	1-3 mo2	[12,13]
EluNIR	Cobalt-chromium	Permanent	Ridaforolimus	Standard/no short DAPT	[14]
Ultimaster; Orsino	Cobalt-chromium	Permanent	Sirolimus	Standard/no short DAPT	[15,16]
Cre8	Cobalt-chromium	Polymer-free	Amphilimus	Standard/no short DAPT	[17]
Xposition S (self-apposing)	Nickel-titanium	Permanent	Silolimus	Standard/no short DAPT	[18]
Promus	Platinium-chromium	Bioresorbable	Everolimus	6 mo	[12]
Synergy	Platinium-chromium	Bioresorbable	Everolimus	3 mo1	[19]

If there was no randomised control trial or prospective trial with a paired control investigating dual antiplatelet therapy (DAPT) duration, DAPT duration validated for is put down as ‘standard/no short DAPT.

¹All trials examined both acute coronary syndrome and chronic coronary syndromes, though the EVOLVE Short DAPT study and the One-Month DAPT trial did not include patients with myocardial infarction.

²The STOPDAPT-2 trial examined 1-mo DAPT followed by P2Y12 inhibitor therapy. DAPT: Dual antiplatelet therapy.